Amendments To The Claims

The listing of claims will replace all prior versions, and listings, of the claims in the application.

Listing Of Claims:

Claims 1-15 (Cancelled)

Claim 16 (Currently Amended) A method for producing needle-shaped crystals of Arg^{34}GLP-1(7-37), said method comprising placing an aqueous solution of said Arg^{34}GLP-1(7-37) at a temperature of between 20-25 degrees centigrade for a time sufficient to allow production of said crystals, wherein said aqueous solution has a pH of between 6 to 7 and comprises in addition to said Arg^{34}GLP-1(7-37), 100-200 mM of an inorganic salt and 1-15% [(w/w)] (vol/vol) ethanol.

Claim 17 (Previously presented) The method of claim 16, wherein said aqueous solution contains 2-10 mg/ml of Arg^{34}GLP-1(7-37).

Claim 18 (Previously presented) The method of claim 17, wherein said aqueous solution comprises between 5-10 % ethanol (vol/vol).

Claim 19 (Previously presented) The method of claim 18, wherein said aqueous solution further comprises a buffer.

Claim 20 (Previously presented) The method of claim 19, wherein said buffer is bis-Tris.

Claim 21 (Previously presented) The method of claim 20 wherein the concentration of said buffer is between 5-10 mM.

Claim 22 (Previously presented) The method of claim 21, wherein said inorganic salt is NaCl.

Claim 23 (Previously presented) The method of claim 22 wherein the pH of said aqueous solution is between 6.2 and 6.6.

Claim 24 (Previously presented) The method of claim 19, wherein said pH of said aqueous solution is

between 6.2 and 6.6.

Claim 25 (Previously presented) The method of claim 24, wherein said inorganic salt is NaCl.

Claim 26 (Previously presented) A method for producing an acylated glucagon-like peptide 1 (GLP-1) analogue, said method comprising:

(a) placing an aqueous solution of said GLP-1 analogue at a temperature of between 20-25 degrees centigrade for a time sufficient to allow production of needle-shaped crystals of said GLP-1 analogue, wherein said GLP-1 analogue in said aqueous solution is Arg^{34}GLP-1(7-37) and said aqueous solution has a pH of between 6 to 7 and comprises in addition to said Arg^{34}GLP-1(7-37), 100-200 mM of an inorganic salt and 1-15% (vol/vol) ethanol; and

(b) acylating the Arg^{34}GLP-1(7-37) that was crystallized in step a).

Claim 27 (Previously presented) The method of claim 26, wherein the Arg^{34}GLP-1(7-37) in the aqueous solution of step a) was recombinantly expressed in yeast.

Claim 28 (Previously presented) The method of claim 26, wherein prior to step a) the GLP-1 analogue Arg^{34}GLP-1(7-37) is precipitated at a pH of about 5.4.

Claim 29 (Previously presented) The method of claim 26, wherein said aqueous solution in step a) contains 2-10 mg/ml of Arg^{34}GLP-1(7-37).

Claim 30 (Previously presented) The method of claim 29, wherein said aqueous solution in step a) comprises between 5-10 % ethanol (vol/vol).

Claim 31 (Previously presented) The method of claim 30, wherein said aqueous solution in step a) further comprises a buffer.

Claim 32 (Previously presented) The method of claim 31, wherein said buffer is bis-Tris.

Claim 33 (Previously presented) The method of claim 32 wherein the concentration of said buffer is between 5-10 mM.

Claim 34 (Previously presented) The method of claim 33 wherein said inorganic salt in step a) is

NaCl.

Claim 35 (Previously presented) The method of claim 34 wherein the pH of said aqueous solution in step a) is between 6.2 and 6.6.

Claim 36 (Previously presented) The method of claim 31, wherein said pH of said aqueous solution is between 6.2 and 6.6.

Claim 37 (Previously presented) The method of claim 36, wherein said inorganic salt is NaCl.

Claim 38 (Previously presented) A method for producing crystals of exendin-4, said method comprising placing an aqueous solution of said exendin-4 at a temperature of between 4-37 degrees centigrade for a time sufficient to allow production of said crystals, wherein said aqueous solution has a pH of pI<pH<pI + 2 and comprises in addition to said exendin-4, at least 25mM of a salt and at least 0.5% (vol/vol) organic solvent.

Claim 39 (Previously presented) The method of claim 38, wherein said aqueous solution contains from 0.5 to 20 mg/ml of exendin-4.

Claim 40 (Previously presented) The method of claim 38, wherein said aqueous solution contains from 2-10 mg/ml of exendin-4.

Claim 41 (Previously presented) The method of claim 38, wherein said salt is an inorganic salt.

Claim 42 (Previously presented) The method of claim 41, wherein said inorganic salt is present in said aqueous solution in a concentration of 100-200 mM.

Claim 43 (Previously presented) The method of claim 38 wherein said aqueous solution comprises 1-15% (vol/vol) of organic solvent.

Claim 44 (Previously presented) The method of claim 38, wherein said aqueous solution has a pH of pI<pH<pI + 2.

Claim 45 (Previously presented) The method of claim 38, wherein said aqueous solution further

comprises a buffer.

Claim 46 (Previously presented) The method of claim 38, wherein said aqueous solution is placed at a temperature of between 20-25 degrees centigrade for a time sufficient to allow production of said crystals.

Claim 47 (Previously presented) The method of claim 40, wherein said aqueous solution is placed at a temperature of between 20-25 degrees centigrade for a time sufficient to allow production of said crystals.

Claim 48 (Previously presented) The method of claim 47, wherein said salt is an inorganic salt.

Claim 49 (Previously presented) The method of claim 48, wherein said inorganic salt is present in said aqueous solution in a concentration of 100-200 mM.

Claim 50 (Previously presented) The method of claim 49 wherein said aqueous solution comprises 1-15% (vol/vol) of organic solvent.

Claim 51 (Previously presented) The method of claim 50, wherein said aqueous solution has a pH of $pI<pH<pI+2$.

Claim 52 (Previously presented) The method of claim 51 wherein said aqueous solution further comprises a buffer.